1. Home
  2. CABR vs AKTX Comparison

CABR vs AKTX Comparison

Compare CABR & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Caring Brands Inc.

CABR

Caring Brands Inc.

N/A

Current Price

$1.13

Market Cap

12.8M

ML Signal

N/A

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

N/A

Current Price

$8.24

Market Cap

15.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CABR
AKTX
Founded
2020
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.8M
15.4M
IPO Year
2025
2014

Fundamental Metrics

Financial Performance
Metric
CABR
AKTX
Price
$1.13
$8.24
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $25.50
AVG Volume (30 Days)
28.9K
★ 39.1K
Earning Date
11-18-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
★ N/A
Revenue
★ $4,215.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.71
$0.12
52 Week High
$1.84
$29.32

Technical Indicators

Market Signals
Indicator
CABR
AKTX
Relative Strength Index (RSI) 46.75 46.63
Support Level $1.08 $6.76
Resistance Level $1.38 $10.49
Average True Range (ATR) 0.16 1.07
MACD -0.00 0.00
Stochastic Oscillator 25.02 41.33

Price Performance

Historical Comparison
CABR
AKTX

About CABR Caring Brands Inc.

Caring Brands Inc is a wellness consumer products company. It offers several over-the-counter (OTC) and cosmetic consumer products. Its product pipeline includes a diverse products, such as hair loss treatments, eczema and psoriasis treatments, vitiligo solutions, a jellyfish sting protective suncare line, and women's sexual wellness products, catering to diverse health and wellness needs. It operates in a single segment.

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

Share on Social Networks: